Elicio Therapeutics Inc (ELTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.41-3.60%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ELTX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -89.5% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ELTX — earnings miss
Dated 2026-05-11
Results of Operations and Financial Condition. On May 11, 2026 , Elicio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026 and provided corporate updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securiti…
Why it matters: Updates on cash runway will show if the company can keep running until Q4 2026. This is important for investor trust.
Supportive ifManagement says they had a successful funding round or cut costs to extend the cash runway.
Worry ifManagement says the cash runway is shorter than expected. This raises worries about money.
Why it matters: The DFS analysis will show if ELI-002 7P helps patients after surgery. This is a key step for future trials.
Watch forThe main DFS analysis shows better rates of staying free from disease.
Also watch forThe DFS analysis shows no better results than the observation group.
Why it matters: Missing earnings could mean bigger problems with operations and plans.
Worry ifThe latest earnings report did not meet what analysts expected for next quarter.
Less concerning ifThe earnings report meets or beats analyst expectations. This shows a turnaround.
Why it matters: If healthcare sector growth speeds up, it may benefit Elicio. This could improve investor sentiment.
Supportive ifHealthcare sector revenue growth is speeding up again. It is now above 10%.
Worry ifHealthcare sector revenue growth is slowing down. It is now below 10%.
Why it matters: This funding will help Elicio with its clinical plans for ELI-002 7P.
Supportive ifThe offering closes on or before July 6, 2026, providing the needed funds.
Worry ifThe offering fails to close or raises significantly less than $15 million.
Why it matters: Good results could help ELI-002 7P treat pancreatic cancer after surgery.
Supportive ifPositive data from the Phase 3 trial on R0 resected patients is reported.
Worry ifThe Phase 3 trial does not show significant benefits for the targeted group.
Why it matters: Getting funds is key. It helps Elicio move forward with clinical programs and stay operational.
Supportive ifLook for news on new financing or partnerships. This will boost cash for clinical work.
Worry ifNot getting more financing or bad news on partnerships could be a problem.
Why it matters: Starting this trial is key for Elicio's strategy in treating metastatic pancreatic cancer. It could validate their approach.
Supportive ifThe Phase 1 combination trial for ELI-002 7P begins as planned in Q4 2026.
Worry ifThe trial does not start by the end of Q4 2026.
Why it matters: Financing is key for Elicio. It helps with Phase 3 development and plans.
Supportive ifA new partnership or financing deal was announced. It helps with clinical development.
Worry ifNo new financing or partnership announcements by the end of Q4 2026.
Why it matters: Knowing the cash runway is important. It helps us see if Elicio can fund its work.
Supportive ifCash and cash equivalents will keep operations running until Q1 2027.
Worry ifThe cash runway extension was not met. This may mean funding problems.
Why it matters: These results will guide the Phase 3 plan. They show how ELI-002 7P may treat pancreatic cancer.
Watch forThe results are good. They show longer disease-free survival for the R0 resected group.
Also watch forNo big change in disease-free survival in the R0 resected group.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$255 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $895 loss on $10,000 · 8.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,377 loss on $10,000 · 83.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.